Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Immune Response Against Viral Pathogens

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Promises of co-stimulatory inhibition for durable and repeatable AAV gene therapy.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

Same author

Intravitreal AAV vector delivery induces integrin-dependent ocular inflammation, complement activation, and antiviral and DNA damage responses.

Frontiers in immunology·2026

Same author

Identification of alterations of immunometabolism associated with Pompe disease.

Cellular and molecular life sciences : CMLS·2026

Same author

Overcoming barriers to commercially pre-viable gene and cell therapies for rare and ultra-rare diseases.

Molecular therapy : the journal of the American Society of Gene Therapy·2025

Same author

AAV vectors trigger DNA damage response-dependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain.

Nature communications·2025

Same author

Inhibition of IFNAR-JAK signaling enhances tolerability and transgene expression of systemic non-viral DNA delivery.

Molecular therapy. Nucleic acids·2025

Same journal

Evaluation of the Toxicity and Efficacy of an Adeno-Associated Viral Vector Expressing <i>BEST1</i> Delivered by Subretinal Injection in a Canine Model of Human Bestrophinopathy.

Human gene therapy·2026

Same journal

The German National Strategy for Gene- and Cell-Based Therapies: Generating Impact by Employing a Novel Multi-Stakeholder Approach.

Human gene therapy·2026

Same journal

Genome Editing for Familial Hemophagocytic Lymphohistiocytosis: Design Principles, Challenges, and Translational Perspectives.

Human gene therapy·2026

Same journal

Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration.

Human gene therapy·2026

Same journal

Hyperthermia-Enhanced Adeno-Associated Virus Gene Therapy: Mechanisms, Delivery Technologies, and Translational Potential.

Human gene therapy·2026

Same journal

Adeno-Associated Virus Gene Therapy Translation: Lessons from Early Regulatory Meetings.

Human gene therapy·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 5, 2025

Author Spotlight: Optimizing Digital Droplet PCR Method for Accurate Adeno-Associated Viral Genome Quantification

Author Spotlight: Optimizing Digital Droplet PCR Method for Accurate Adeno-Associated Viral Genome Quantification

Published on: October 11, 2024

Complement System Response to Adeno-Associated Virus Vector Gene Therapy.

Elizabeth Kropf¹, David M Markusic¹, Anna Majowicz¹

¹Immunology Department, Spark Therapeutics, Inc., Philadelphia, Pennsylvania, USA.

Human Gene Therapy

|January 22, 2024

Summary

This summary is machine-generated.

Adeno-associated virus (AAV) gene therapy faces challenges from immune responses, particularly complement system activation. Understanding AAV-specific, environmental, and patient factors is crucial for mitigating adverse events and improving therapeutic efficacy.

Keywords:

AAV complement gene therapy immune response innate immunity

More Related Videos

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

Published on: October 26, 2018

Author Spotlight: Unveiling the Potential of Unpurified Recombinant AAVs in Cell Culture Research

Author Spotlight: Unveiling the Potential of Unpurified Recombinant AAVs in Cell Culture Research

Published on: October 20, 2023

Related Experiment Videos

Last Updated: Jul 5, 2025

Author Spotlight: Optimizing Digital Droplet PCR Method for Accurate Adeno-Associated Viral Genome Quantification

Author Spotlight: Optimizing Digital Droplet PCR Method for Accurate Adeno-Associated Viral Genome Quantification

Published on: October 11, 2024

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

Published on: October 26, 2018

Author Spotlight: Unveiling the Potential of Unpurified Recombinant AAVs in Cell Culture Research

Author Spotlight: Unveiling the Potential of Unpurified Recombinant AAVs in Cell Culture Research

Published on: October 20, 2023

Area of Science:

Immunology
Gene Therapy
Biotechnology

Background:

Adeno-associated virus (AAV) vectors are promising for genetic therapeutics.
Immune-related toxicities, including complement activation, can limit AAV gene therapy efficacy.
Managing AAV-induced liver enzyme elevations is established, but complement activation presents a new challenge.

Purpose of the Study:

Investigate the role of the complement system in AAV gene therapy adverse events.
Explore factors contributing to complement activation by AAV vectors.
Identify strategies to mitigate AAV-related immune responses.

Main Methods:

Review of in vitro, in vivo, pre-clinical, and clinical studies on AAV and complement activation.
Analysis of factors influencing complement responses, including AAV-specific, environmental, and patient-specific elements.

Main Results:

Both classical and alternative complement pathways are implicated in AAV-mediated immune responses.
A complex interplay of factors dictates complement activation and clinical outcomes.
Adverse events like hepatotoxicity and thrombotic microangiopathy are linked to complement activation.

Conclusions:

Complement activation is a significant challenge in high-dose AAV gene therapy.
Further research is needed on the interaction between patient-specific and AAV-related factors.
Targeting complement cascade components may offer strategies to mitigate AAV-related immune responses.